AntibodiesAssay KitscDNACulture CellsDevicesEnzymesExosomesIsotypesMedium & SerumsNATtrolPanelPCRPcr KitsReagentsRia KitsTest KitsVector & Virus

Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs

Background: Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in sub-Saharan African kids can vary as much as 50% by age 2 years however components affecting early age of KSHV an infection should not effectively understood. Malaria throughout being pregnant has been related to hindered transplacental switch of antibodies to a number of pathogens however whether or not it impacts transplacental switch of KSHV antibodies is unknown. We aimed to find out if in utero malaria publicity decreased the switch of KSHV antibodies throughout the placenta.
Strategies: A cohort examine in Kisumu, Kenya enrolled pregnant ladies at their first antenatal clinic (ANC) go to and adopted them via supply. We included 70 KSHV-positive, HIV-negative moms and their kids. KSHV antibody ranges have been measured by ELISA (K8.1, ORF73) and multiplex assay. Transplacental switch of antibodies was measured by the wire to maternal blood ratio (CMR) of KSHV antibodies. Malaria throughout being pregnant was outlined as detection of Plasmodium falciparum (Pf) DNA at any ANC go to or supply. Amongst ladies with malaria throughout being pregnant, we examined time of final malaria an infection previous to supply and malaria incidence fee.
Outcomes: KSHV seroprevalence (constructive for K8.1 or ORF73 by ELISA) amongst pregnant ladies was 88%. Neither malaria throughout being pregnant, malaria an infection timing, nor MIR have been related to maternal supply KSHV antibody blood ranges. Maternal supply and twine blood KSHV antibody ranges have been extremely correlated however these correlations didn’t differ by malaria throughout being pregnant. KSHV transplacental antibody switch was not related to malaria throughout being pregnant, malaria an infection timing, nor MIR.
Conclusions: Malaria throughout being pregnant doesn’t seem to have an effect on switch of KSHV antibodies throughout the placenta.

Dynamic modifications in anti-SARS-CoV-2 antibodies throughout SARS-CoV-2 an infection and restoration from COVID-19

Deciphering the dynamic modifications in antibodies in opposition to SARS-CoV-2 is important for understanding the immune response in COVID-19 sufferers. Right here we analyze the laboratory findings of 1,850 sufferers to explain the dynamic modifications of the whole antibody, spike protein (S)-, receptor-binding area (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) ranges throughout SARS-CoV-2 an infection and restoration. The era of S-, RBD-, and N-specific IgG happens one week later in sufferers with extreme/essential COVID-19 in comparison with sufferers with gentle/average illness, whereas S- and RBD-specific IgG ranges are 1.5-fold greater in extreme/essential sufferers throughout hospitalization. The RBD-specific IgG ranges are 4-fold greater in older sufferers than in youthful sufferers throughout hospitalization.
As well as, the S- and RBD-specific IgG ranges are 2-fold greater within the recovered sufferers who’re SARS-CoV-2 RNA damaging than those that are RNA constructive. Decrease S-, RBD-, and N-specific IgG ranges are related to a decrease lymphocyte proportion, greater neutrophil proportion, and an extended period of viral shedding. Sufferers with low antibody ranges on discharge would possibly thereby have a excessive probability of being examined constructive for SARS-CoV-2 RNA after restoration. Our examine gives necessary data for COVID-19 analysis, remedy, and vaccine growth.
Throughout the coronavirus illness 2019 (COVID-19) pandemic, many international locations skilled an infection in healthcare staff (HCW) resulting from overburdened healthcare techniques. Nevertheless, whether or not contaminated HCW purchase protecting immunity in opposition to SARS-CoV-2 is unclear. Right here, we characterised SARS-CoV-2-specific antibody responses in Norwegian HCW in a potential cohort examine.
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs

A randomized, multicentre, open-label section II proof-of-concept trial investigating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19: the Donated Antibodies Working in opposition to nCoV (DAWn-Plasma) trial

Background: The COVID-19 pandemic has imposed an infinite burden on well being care techniques all over the world. Up to now, the administration of convalescent plasma of sufferers having recovered from SARS and extreme influenza to sufferers actively having the illness confirmed promising results on mortality and appeared secure. Whether or not or not this additionally holds true for the novel SARS-CoV-2 virus is at present unknown.
Strategies: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, section II proof-of-concept medical trial, evaluating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19 in Belgium. Sufferers hospitalized with a confirmed analysis of COVID-19 are eligible when they’re symptomatic (i.e. medical or radiological indicators) and have been recognized with COVID-19 within the 72 h earlier than examine inclusion via a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan displaying options suitable with COVID-19 within the absence of an alternate analysis. Sufferers are randomized in a 2:1 ratio to both customary of care and convalescent plasma (energetic remedy group) or customary of care solely. The energetic remedy group receives 2 items of 200 to 250 mL of convalescent plasma inside 12 h after randomization, with a second administration of two items 24 to 36 h after ending the primary administration. The trial goals to incorporate 483 sufferers and can recruit from 25 centres throughout Belgium. The first endpoint is the proportion of sufferers that require mechanical air flow or have died at day 15. The primary secondary endpoints are medical standing on day 15 and day 30 after randomization, as outlined by the WHO Development 10-point ordinal scale, and security of the administration of convalescent plasma.

MIP-3-alpha/CCL20, Human

HY-P7262 10ug
EUR 321.6

MIP-3/CCL23, human recombinant

7175-10 each
EUR 248.4

MIP-3/CCL23, human recombinant

7175-50 each
EUR 810

Goat Anti Human Mip-1 Alpha Polyclonal Antibody

CPBT-65207GH 0.1 mg
EUR 1057.2

MIP-3

PAab09791 100 ug
EUR 463.2

MIP-3

EF012726 96 Tests
EUR 826.8

MIP-3

EF013760 96 Tests
EUR 826.8

MIP-3

EF013761 96 Tests
EUR 826.8

MIP-3

EF016652 96 Tests
EUR 826.8

MIP-3

EF016984 96 Tests
EUR 826.8

MIP-3

EF010865 96 Tests
EUR 826.8

MIP-3

EF017888 96 Tests
EUR 826.8

MIP-3

ant-121 0.5mg
EUR 275
Description: Mouse Anti-Human Macrophage Inflammatory Protein-3

Rabbit Anti Human Mip-1 Beta Polyclonal Antibody

CPBT-65212RH 0.1 mg
EUR 1057.2

anti- MIP antibody

FNab05193 100µg
EUR 658.5
Description: Antibody raised against MIP

Human CCL19/ MIP-3 ELISA KIT

E42EH-62 96T/48T Ask for price

Recombinant Human MIP-3 alpha (CCL20)

HECCP-2001 5ug Ask for price

anti- MIP-3α antibody

FNab09791 100µg
EUR 658.5
Description: Antibody raised against MIP-3α

Recombinant Human MIP-3 (CCL23) Protein

PROTP55773-1 20ug
EUR 380.4
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

MIP-3/CCL23 (CHO-expressed), Human

HY-P7259 10ug
EUR 321.6

Human MIP-3 Recombinant Protein Lyophilized

IHUMIP3RLY5UG each
EUR 341
Description: Human MIP-3 Recombinant Protein Lyophilized

MIP 3

chm-358 5µg
EUR 60
Description: Recombinant Human Macrophage Inflammatory protein-3 (CCL23)

Human MIP-3 alpha/CCL20 ELISA Kit

RK00207 96 Tests
EUR 625.2

Human CCL19/MIP-3 β ELISA Kit

E16HE0218 96T
EUR 833.33

Human MIP-3B (CCL23)

90219-A 5 µg
EUR 130
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.

Human MIP-3B (CCL23)

90219-B 20 µg
EUR 205
Description: Recombinant MIP-3 alpha (CCL20) is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 alpha mature chain was expressed in E. coli.

Human MIP-3A(CCL20)

90220-A 5 µg
EUR 130
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.

Human MIP-3A(CCL20)

90220-B 25 µg
EUR 205
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.

Human CCL19/MIP-3 beta ELISA Kit

LF-EK50840 1×96T
EUR 777.6

MIP-3-beta Antibody

abx235194-100ug 100 ug
EUR 577.2

MIP-4/CCL18, Human

HY-P7265 50ug
EUR 639.6

MIP-5/CCL15, Human

HY-P7266 50ug
EUR 555.6

MIP-5, CCL15, human

RC315-26 5ug
EUR 125.26

Recombinant Human MIP-3 Beta (CCL19) Protein

PROTQ99731-1 20ug
EUR 380.4
Description: MIP-3β is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3β is active on murine cells. Recombinant human MIP-3β is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Recombinant Human MIP-3 Alpha (CCL20) Protein

PROTP78556-2 20ug
EUR 380.4
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

MIP-3? Polyclonal Antibody

ES8712-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against MIP-3? from Human/Mouse. This antibody is tested and validated for IHC, WB, ELISA

MIP-3? Polyclonal Antibody

ES8712-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against MIP-3? from Human/Mouse. This antibody is tested and validated for IHC, WB, ELISA

MIP-3? Polyclonal Antibody

ES7130-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against MIP-3? from Human. This antibody is tested and validated for IHC, WB, ELISA

MIP-3? Polyclonal Antibody

ES7130-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against MIP-3? from Human. This antibody is tested and validated for IHC, WB, ELISA

Human MIP-3 beta Recombinant Protein Lyophilized

IHUMIP3BRLY5UG each
EUR 341
Description: Human MIP-3 beta Recombinant Protein Lyophilized

MIP-3-alpha/CCL20 (CHO-expressed), Human

HY-P7260 10ug
EUR 321.6

Human MIP-3 alpha Recombinant Protein Lyophilized

IHUMIP3ARLY5UG each
EUR 341
Description: Human MIP-3 alpha Recombinant Protein Lyophilized

Recombinant Human CCL19/MIP-3 beta Protein

RP01634 100μg
EUR 39

MIP-1beta, human recombinant

4247-10 each
EUR 379.2

MIP-1beta, human recombinant

4247-1000 each
EUR 6558

MIP-3beta, human recombinant

4494-1000 each
EUR 6558

MIP-3beta, human recombinant

4494-20 each
EUR 379.2

Human MIP-1β ELISA Kit

EHM0017 96Tests
EUR 625.2

Human MIP-3α ELISA Kit

EHM0019 96Tests
EUR 625.2

Human MIP-3β ELISA Kit

EHM0020 96Tests
EUR 625.2

MIP-1alpha, human recombinant

4244-100 each
EUR 1038

MIP-1alpha, human recombinant

4244-1000 each
EUR 5572.8

MIP-1alpha, human recombinant

4244-20 each
EUR 379.2

MIP-3alpha, human recombinant

4491-1000 each
EUR 4653.6

MIP-3alpha, human recombinant

4491-20 each
EUR 320.4

ELISA kit for Human MIP-3 Alpha/CCL20

EK5191 96 tests
EUR 663.6
Description: Enzyme-linked immunosorbent assay kit for quantification of Human MIP-3 Alpha/CCL20 in samples from serum, plasma, tissue homogenates and other biological fluids.

Anti-CXCL2 / MIP-2 antibody

STJ71916 100 µg
EUR 430.8

ELISA kit for Human CCL19/MIP-3 Beta

EK5194 96 tests
EUR 663.6
Description: Enzyme-linked immunosorbent assay kit for quantification of Human CCL19/MIP-3 Beta in samples from serum, plasma, tissue homogenates and other biological fluids.

Human MIP-3 alpha/CCL20 PicoKine ELISA Kit

EK0453 96 wells
EUR 523.2
Description: For quantitative detection of human MIP-3 alpha in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA).

Human MIP-2 ELISA Kit

EHM0018 96Tests
EUR 625.2

Human MIP-4 ELISA Kit

EHM0021 96Tests
EUR 625.2

Human MIP-5 ELISA Kit

EHM0022 96Tests
EUR 625.2

MIP ELISA KIT|Human

EF000798 96 Tests
EUR 826.8

Human MIP shRNA Plasmid

20-abx952903
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Human MIP-1a ELISA kit

LF-EK50245 1×96T
EUR 777.6

Human MIP-3a ELISA kit

LF-EK50249 1×96T
EUR 777.6

Human CCL3/MIP-1αELISA KIT

E42EH-66 96T/48T Ask for price

Human CCL4/MIP-1βELISA KIT

E42EH-67 96T/48T Ask for price

Human Eotaxin-3 / MIP-4a (CCL26) ELISA Kit

abx252760-96tests 96 tests
EUR 764.4

Human Eotaxin-3 / MIP-4a (CCL26) ELISA Kit

abx575008-96tests 96 tests
EUR 801.6

Human Eotaxin-3 / MIP-4a (CCL26) ELISA Kit

abx351155-96tests 96 tests
EUR 801.6

Human CCL19/MIP-3 beta PicoKine ELISA Kit

EK0456 96 wells
EUR 510
Description: For quantitative detection of human CCL19 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA).

MIP-1 beta, CCL4, human

RC314-15 2ug
EUR 121.6

MIP-1 alpha, CCL3, human

RC315-14 5ug
EUR 125.26

MIP-4, PARC, CCL18, human

RC315-29 2ug
EUR 125.26

Human Macrophage Inflammatory Protein 3(MIP-3) ELISA Kit

NSL0463Hu 96 wells
EUR 468

Ccl19 Antibody / Mip-3 beta

R32903 100 ug
EUR 356.15
Description: Chemokine (C-C motif) ligand 19 (CCL19) is a protein that in humans is encoded by the CCL19 gene. This gene is one of several CC cytokine genes clustered on the p-arm of chromosome 9. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene may play a role in normal lymphocyte recirculation and homing. It also plays an important role in trafficking of T cells in thymus, and in T cell and B cell migration to secondary lymphoid organs. It specifically binds to chemokine receptor CCR7.

Human Macrophage Inflammatory Protein-3?,MIP-3? ELISA kit

201-12-0086 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human Macrophage Inflammatory Protein-3?,MIP-3? ELISA kit

201-12-0087 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

MIP-1-beta/CCL4, Human

HY-P7257 10ug
EUR 321.6

Ccl20 Antibody / Mip-3 alpha

R32858 100 ug
EUR 356.15
Description: Macrophage Inflammatory Protein 3 alpha (MIP-3 alpha), is also called Chemokine, cc motif, ligand 20 (CCL20). The MIP-3 alpha / CCL20 gene was cloned and sequenced, revealing a four exon, three intron structure, and was localized by FISH analysis to 2q35-q36. MIP3 alpha is predominantly expressed in lymph nodes, appendix, PBL, fetal liver, fetal lung and several cell lines. MIP3 alpha / CCL20 and its receptor CCR6 are markedly up-regulated in psoriasis, and they may play a role in the recruitment of T cells to lesional psoriatic skin.

Recombinant Human MIP-5 (CCL15)

HECCP-1501 5ug Ask for price

Recombinant Human MIP-4 (CCL18)

HECCP-1801 10ug Ask for price

MIP-1-alpha/CCL3, Human

HY-P7256 10ug
EUR 280.8

MIP-3beta (Human) ELISA Kit

EKA51971-5x96T 5x96T Ask for price

MIP-3beta (Human) ELISA Kit

EKA51971-96T 96T
EUR 446.9

MIP-1alpha (Human) ELISA Kit

EKA51868-5x96T 5x96T Ask for price

MIP-1alpha (Human) ELISA Kit

EKA51868-96T 96T
EUR 446.9

MIP-1delta (Human) ELISA Kit

EKA51969-5x96T 5x96T Ask for price

MIP-1delta (Human) ELISA Kit

EKA51969-96T 96T
EUR 446.9

MIP-3alpha (Human) ELISA Kit

EKA51970-5x96T 5x96T Ask for price

MIP-3alpha (Human) ELISA Kit

EKA51970-96T 96T
EUR 446.9

MIP sgRNA CRISPR Lentivector (Human) (Target 3)

K1304004 1.0 ug DNA
EUR 184.8

MIP-4 (PARC), human recombinant

4257-10 each
EUR 405.6

MIP-4 (PARC), human recombinant

4257-1000 each
EUR 7100.4

MIP-1?/CCL3, human recombinant

7173-10 each
EUR 248.4

MIP-1?/CCL3, human recombinant

7173-50 each
EUR 810

MIP Recombinant Protein (Human)

RP041341 100 ug Ask for price

MIP-5/CCL15, human recombinant

4260-1000 each
EUR 4431.6

MIP-5/CCL15, human recombinant

4260-25 each
EUR 307.2

Human MIP-1α(CCL3) ELISA kit

E22-HC112a.48 48T
EUR 295

Human MIP-1α(CCL3) ELISA kit

E22-HC112a.96 96T
EUR 395

Human MIP-1β/CCL4 ELISA kit

E22-HC155b.48 48T
EUR 295

Human MIP-1β/CCL4 ELISA kit

E22-HC155b.96 96T
EUR 395

Human MIP-3α/CCL20 ELISA Kit

E16HE0061 96T
EUR 833.33

rHu MIP-3-beta

AK8232-0005 5µg Ask for price

rHu MIP-3-beta

AK8232-0020 20µg Ask for price

rHu MIP-3-beta

AK8232-0100 100µg Ask for price

rHu MIP-3-beta

AK8232-1000 1mg Ask for price

rHu MIP-3-alpha

AK8271-0005 5µg Ask for price

rHu MIP-3-alpha

AK8271-0020 20µg Ask for price

rHu MIP-3-alpha

AK8271-0100 100µg Ask for price

rHu MIP-3-alpha

AK8271-1000 1mg Ask for price

Anti-Aquaporin 0/MIP Antibody

PB9811 100ug/vial
EUR 352.8

Anti-Aquaporin 0/MIP Antibody

PA2110 100ug/vial
EUR 352.8

Human CCL3/MIP-1α ELISA Kit

E28L0230 96T
EUR 666.67

Human CCL4/MIP-1β ELISA Kit

E28L0275 96T
EUR 666.67

Human CCL20/MIP-3α ELISA Kit

E28L0325 96T
EUR 666.67

Human MIP-1a ELISA kit (4X96T)

LF-EK50246 4×96T
EUR 2641.2

Human MIP-3a ELISA kit (4X96T)

LF-EK50250 4×96T
EUR 2641.2

Human MIP-1d/CCL15 ELISA KIT

E42EH-285 96T/48T Ask for price

Human MIP-3a/CCL20 ELISA KIT

E42EH-287 96T/48T Ask for price

Anti-CCL19/Mip 3 Beta Rabbit Monoclonal Antibody

M01605 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal CCL19/Mip 3 Beta Antibody. Validated in WB and tested in Human.

MIP-3 Recombinant Protein

40-379-0005mg 0.005 mg
EUR 311.1
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

MIP-3 Recombinant Protein

40-379-002mg 0.02 mg
EUR 437.1
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

MIP-1β/CCL4 (CHO-expressed), Human

HY-P7389 50ug
EUR 596.4

Human MIP Protein Lysate 20ug

IHUMIPPLLY20UG each
EUR 213
Description: Human MIP Protein Lysate 20ug

MIP ORF Vector (Human) (pORF)

ORF013781 1.0 ug DNA
EUR 424.8

MIP-1 beta (human) ELISA Kit

K4785-100 100 assays
EUR 970.8
Description: Sensitive, Colorimetric Assay

Recombinant Human CCL15/ MIP-5/ MIP-1 delta Protein, Untagged, E.coli-5ug

QP10200-ec-5ug 5ug
EUR 184.8

MIP-1 alpha (human) ELISA Kit

K4784-100 100 assays
EUR 1000.8
Description: Sensitive, Colorimetric Assay

Recombinant Human MIP-1 beta/CCL4

HECCP-0401 10ug Ask for price
Dialogue: This trial will both present assist or discourage the usage of convalescent plasma as an early intervention for the remedy of hospitalized sufferers with COVID-19 an infection.
Tara

Leave a Reply

Your email address will not be published.